Please check your internet connection and try again.
## Septran (Co-trimoxazole)
### Overview
Septran is a combination antibiotic containing sulfamethoxazole and trimethoprim, which work synergistically to inhibit bacterial folic acid synthesis. It is available in various formulations, including tablets, oral suspension, and intravenous solutions.
### Primary Indications
* **Urinary Tract Infections (UTIs):** Acute uncomplicated UTIs, and prophylaxis.
* **Pneumocystis jirovecii Pneumonia (PCP):** Treatment and prophylaxis in immunocompromised patients.
* **Bacterial Infections:** Treatment of certain respiratory tract infections (e.g., acute exacerbations of chronic bronchitis), ear infections (otitis media), and traveler's diarrhea.
### Adult Dosing
* **Uncomplicated UTIs:** 1 double-strength (DS) tablet (160 mg trimethoprim/800 mg sulfamethoxazole) every 24 hours for 3 days, or 2 single-strength tablets (80 mg trimethoprim/400 mg sulfamethoxazole) twice daily for 3 days.
* **PCP Treatment:** 15 mg/kg/day trimethoprim component, divided into 3-4 doses, given orally or IV for 14-21 days.
* **PCP Prophylaxis:** 1 DS tablet once daily, or 1 DS tablet three times weekly.
* **Other Infections:** Dosing varies by infection. A common regimen is 1-2 DS tablets every 12 hours.
### Pediatric Dosing
* **UTIs and other common infections:** 8 mg/kg/day trimethoprim component and 40 mg/kg/day sulfamethoxazole component, divided into two equally divided doses, given orally every 12 hours.
* **PCP Treatment:** 15 mg/kg/day trimethoprim component and 75 mg/kg/day sulfamethoxazole component, divided into 3-4 doses, given orally or IV for 14-21 days.
* **PCP Prophylaxis:** 150 mg/m²/day trimethoprim component and 750 mg/m²/day sulfamethoxazole component, divided into two oral doses daily for 3 consecutive days a week.
* **Note:** Pediatric dosing for infants under 2 months is generally not recommended due to risk of kernicterus.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Reduce dose by 50%.
* CrCl < 15 mL/min: Avoid use.
* **Hepatic Impairment:** Use with caution.
### Contraindications
* Known hypersensitivity to trimethoprim or sulfonamides.
* History of drug-induced immune thrombocytopenia with prior use of trimethoprim or sulfonamides.
* Megaloblastic anemia due to folate deficiency.
* Infants less than 2 months of age (risk of kernicterus).
* Severe renal or hepatic insufficiency when adequate laboratory facilities are unavailable.
### Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, rash.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), hypersensitivity reactions, blood dyscrasias (leukopenia, thrombocytopenia, aplastic anemia, agranulocytosis), hyperkalemia, hepatotoxicity, crystalluria (ensure adequate fluid intake).
### Key Drug Interactions
* **Warfarin:** Increased INR. Monitor INR closely.
* **Methotrexate:** Increased risk of methotrexate toxicity.
* **Potassium-sparing diuretics:** Increased risk of hyperkalemia.
* **ACE inhibitors and ARBs:** Increased risk of hyperkalemia.
* **Cyclosporine:** Increased risk of nephrotoxicity.
* **Sulfonylureas:** Increased risk of hypoglycemia.
### Monitoring
* Complete blood counts (CBC) with differential before and during therapy, especially for prolonged treatment.
* Renal and hepatic function.
* Electrolytes (especially potassium).
* Signs of hypersensitivity reactions and skin reactions.
* For patients on warfarin, monitor INR.
### Clinical Pearls
* Advise patients to drink plenty of fluids to prevent crystalluria.
* Caution regarding sun exposure due to photosensitivity.
* Emphasize completion of the full course of therapy, even if symptoms improve.
* Discontinue immediately if rash or other signs of serious hypersensitivity occur.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions. Local protocols may vary.
